On March 6, 2018 Keryx Biopharmaceuticals, Inc, (NASDAQ:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, reported it will webcast its corporate presentation at the 38th Annual Cowen Healthcare Conference in Boston on Monday, March 12, 2018 at 1:30 p.m. ET (Press release, , JUN 6, 2018, View Source [SID1234524623]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of both the presentation and breakout session will be accessible from Keryx’s website at View Source within the Investor Relations section under "webcasts and presentations." Archived versions of the webcasts will be available for at least 15 days following the conclusion of each session

The journnal Cancer Chemotherapy and Pharmacology has recently published the randomized, double-blind, phase III and comparative clinical study of pharmacokinetics and pharmacodynamics between RTXM83 rituximab biosimilar and its reference product in diffuse large B-cell lymphoma patients (Press release, mAbxience, MAR 6, 2018, View Source [SID1234525381])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

.
The main objective was to quantify any potential differences in pharmacokinetic (PK) parameters (AUC and Cmax). To demonstrate biosimilarity at pharmacokinetic level as required by regulatory agencies, a population pharmacokinetic analysis was performed to compare RTXM83 with respect to the reference product. For this purpose, 5,431 serum samples from 251 recruited patients were used. The systemic exposure of RTXM83 and its associated variability were similar to those for rituximab reference, demonstrating PK similarity. The PD similarity of RTXM83 and rituximab reference product was also demonstrated.

On March 6, 2018 AVEO Oncology (NASDAQ: AVEO) reported that Michael Bailey, president and chief executive officer, will present at the Cowen and Company 38th Annual Health Care Conference in Boston on Tuesday, March 13, 2018 at 10:40 a.m. Eastern Time (Press release, AVEO, MAR 6, 2018, View Source;p=RssLanding&cat=news&id=2336395 [SID1234524409]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. A replay of the webcast will be archived for 30 days following the presentation date.

On March 6, 2018 Blueprint Medicines Corporation (NASDAQ:BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, reported that Jeff Albers, Blueprint Medicines’ Chief Executive Officer, will present a company overview at the Cowen and Company 38th Annual Health Care Conference on Tuesday, March 13, 2018 at 11:20 a.m. EST (Press release, Blueprint Medicines, MAR 6, 2018, View Source;p=RssLanding&cat=news&id=2336442 [SID1234524439]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available by visiting the Investors section of Blueprint Medicines’ website at View Source A replay of the webcast will be archived on Blueprint Medicines’ website for 30 days following the presentation.

On march 6, 2018 Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) reported that the company is scheduled to participate in an analyst-led fireside chat at the 2018 Barclays Global Healthcare Conference at 11:15 AM ET on Tuesday, March 13, 2018 in Miami (Press release, Pacira Pharmaceuticals, MAR 6, 2018, View Source;p=RssLanding&cat=news&id=2336413 [SID1234524459]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the Pacira presentation can be accessed by visiting the "Investors & Media" section of the company’s website at investor.pacira.com. A replay of the webcast will be archived on the Pacira website for two weeks following the presentation date.